Jade Biosciences (JBIO) EBITDA (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of EBITDA data on file, last reported at -$40.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 7.0% year-over-year to -$40.8 million; the trailing twelve-month figure through Mar 2026 stood at -$130.0 million (down 26.65% YoY), and the FY2025 full-year result was -$127.3 million, down 82.46% from the prior year.
• EBITDA for Q1 2026 stood at -$40.8 million, down from -$31.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$590000.0 in Q2 2024 and bottomed at -$47.0 million in Q4 2024.
• The 5-year median for EBITDA is -$19.6 million (2023), against an average of -$22.5 million.
• The widest annual swing landed in 2024, when EBITDA jumped 96.9%; it then sank 5350.51% in 2025.
• A 5-year view of EBITDA shows it stood at -$14.7 million in 2022, then tumbled by 35.58% to -$20.0 million in 2023, then plunged by 135.45% to -$47.0 million in 2024, then soared by 32.24% to -$31.8 million in 2025, then declined by 28.3% to -$40.8 million in 2026.
• The last three EBITDA figures came in at -$40.8 million (Q1 2026), -$31.8 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.

Peer Comparison